CELG DMA
As of date:11/20/2019
CELG stock price:108.24
CELG 50 DMA:103.23
CELG 200 DMA:95.60
CELG MACD (200-50):-7.63

Also see:
CELG Market Cap History
CELG Shares Outstanding History
CELG YTD Return
CELG RSI
CELG MACD
CELG Technical Analysis

DraftKings Breaks Above 200-Day Moving Average - Bullish for DKNG
1 hour, 8 minutes ago


NGMS Crosses Above Key Moving Average Level
1 hour, 8 minutes ago


DT Makes Bullish Cross Above Critical Moving Average
1 hour, 13 minutes ago


Repligen (RGEN) Shares Cross Above 200 DMA
1 hour, 14 minutes ago


CVCO Crosses Above Key Moving Average Level
1 hour, 15 minutes ago


Alexander & Baldwin Breaks Above 200-Day Moving Average - Bullish for ALEX
1 hour, 16 minutes ago


KGC Crosses Above Key Moving Average Level
1 hour, 23 minutes ago


SR Crosses Below Key Moving Average Level
1 hour, 23 minutes ago


Bullish Two Hundred Day Moving Average Cross - PCY
1 hour, 23 minutes ago


Minerals Technologies Breaks Above 200-Day Moving Average - Bullish for MTX
1 hour, 23 minutes ago


iShares iBonds Dec 2022 Term Corporate Breaks Below 200-Day Moving Average - Notable for IBDN
1 hour, 23 minutes ago


Suncor Energy (SU.CA) Shares Cross Below 200 DMA
1 hour, 23 minutes ago


FROG Crosses Above Key Moving Average Level
3 hours, 38 minutes ago


Freshworks Breaks Above 200-Day Moving Average - Bullish for FRSH
3 hours, 42 minutes ago


VRSK Makes Bullish Cross Above Critical Moving Average
4 hours, 18 minutes ago


More Technical Analysis News

CELG DMACELG MACD
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

When researching a stock like Celgene, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from CELG Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for CELG stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the CELG 200 day moving average ("CELG 200 DMA"), while one of the most popular "shorter look-backs" is the CELG 50 day moving average ("CELG 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Celgene.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quotes delayed 20 minutes

Email EnvelopeFree CELG Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
 

CELG DMA | www.StockDMA.com | Copyright © 2019 - 2022, All Rights Reserved

Nothing in StockDMA.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.